|
| |
Gene Bridges licenses Red/ET Recombineering to
Genencor
Heidelberg, March 31, 2008 - Gene Bridges GmbH, the recombineering company,
today announced that Genencor International Inc. USA, a part of Danisco US Inc.,
has completed a commercial license agreement for the use of the Red/ET
recombination technology from Gene Bridges.
Under the terms of the agreement, Gene Bridges has licensed the Red/ET
technology to Genencor for the purpose of genetically engineering recombinant
micro-organisms for use in industrial applications. No financial details were
disclosed.
Gary Stevens, CEO of Gene Bridges GmbH, commented:
‘We are very pleased to add Danisco to the list of major industrial
biotechnology companies using Red/ET. Recombineering is the technology of choice
in DNA engineering and is used worldwide in industry and academia.’
Red/ET is a revolutionary method for DNA engineering. Recombineering with Red/ET
allows unlimited cloning, subcloning, and modification of DNA at any chosen
position. It permits precise engineering of DNA molecules of any size, including
very large ones such as BACs or the E.coli chromosome. Recombineering DNA using
Red/ET has a number of advantages over conventional methods:
· Independent of restriction sites
· No size limits
· No unwanted mutations
· Rapid
Red/ET Recombineering is one simple and powerful tool to modify plasmids, BACs,
and even E.coli chromosomes.
About Gene Bridges GmbH
Gene Bridges GmbH is a self-financed biotech company pioneering recombineering,
the fast and precise method of engineering gene sequences. The Company was
founded in 2000 as spin-off from the European Molecular Biology Laboratory (EMBL)
in Heidelberg, Germany. Gene Bridges commercialises its patented recombineering
technology from its facilities in Heidelberg as well as through its distributors
worldwide. Further information can be found by visiting
www.genebridges.com .
Further Information:
Gary Stevens
CEO, Gene Bridges GmbH
t: +49 (0)6221-13708 10
e: gary.stevens@genebridges.com
Douglas Pretsell
Account Director, Munich Bureau Chief
College Hill Life Sciences
t : +49 (0)89 57 00 18 06
e: douglas.pretsell@collegehill.com | |
|
